NASDAQ:CELC

Celcuity Stock Forecast, Price & News

$26.90
-0.69 (-2.50 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.90
$27.50
50-Day Range
$14.25
$29.28
52-Week Range
$5.00
$30.62
Volume32,952 shs
Average Volume64,028 shs
Market Capitalization$340.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
30 days | 90 days | 365 days | Advanced Chart
Receive CELC News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.


Celcuity logo

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.97 out of 5 stars

Medical Sector

1149th out of 2,099 stocks

Medical Laboratories Industry

20th out of 40 stocks

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Celcuity (NASDAQ:CELC) Frequently Asked Questions

Is Celcuity a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Celcuity stock.
View analyst ratings for Celcuity
or view top-rated stocks.

What stocks does MarketBeat like better than Celcuity?

Wall Street analysts have given Celcuity a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Celcuity wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Celcuity's next earnings date?

Celcuity is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for Celcuity
.

How were Celcuity's earnings last quarter?

Celcuity Inc. (NASDAQ:CELC) posted its quarterly earnings data on Sunday, May, 9th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01.
View Celcuity's earnings history
.

How has Celcuity's stock been impacted by Coronavirus (COVID-19)?

Celcuity's stock was trading at $7.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CELC stock has increased by 277.8% and is now trading at $26.90.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CELC?

2 Wall Street analysts have issued 12-month price objectives for Celcuity's shares. Their forecasts range from $24.00 to $30.00. On average, they expect Celcuity's share price to reach $27.00 in the next year. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Celcuity
or view top-rated stocks among Wall Street analysts.

Who are Celcuity's key executives?

Celcuity's management team includes the following people:
  • Mr. Brian F. Sullivan, Co-Founder, Chairman & CEO (Age 59, Pay $250k)
  • Dr. Lance G. Laing, Co-Founder, Chief Science Officer, VP, Sec. & Director (Age 59, Pay $333.9k)
  • Ms. Vicky Hahne, Chief Financial Officer (Age 55, Pay $177.65k)
  • Mr. Eric Lindquist, Chief Bus. Officer
  • Dr. Arthur P. DeCillis, Chief Medical Officer (Age 65)
  • Dr. John R. MacDonald Ph., Dabt, Sr. VP of R&D (Age 66)
  • Ms. Sheri Smith, Acting Head of Clinical Operations
  • Ms. Marie DeGayner Kuker, Head of Regulatory
  • Mr. Bernhard Lampert Ph.D., Head of CMC

Who are some of Celcuity's key competitors?

What other stocks do shareholders of Celcuity own?

When did Celcuity IPO?

(CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is Celcuity's stock symbol?

Celcuity trades on the NASDAQ under the ticker symbol "CELC."

Who are Celcuity's major shareholders?

Celcuity's stock is owned by a number of retail and institutional investors. Top institutional investors include Frontier Wealth Management LLC (5.91%), Gagnon Securities LLC (3.28%), Federated Hermes Inc. (2.25%), Gagnon Advisors LLC (1.80%), Granite Point Capital Management L.P. (1.67%) and Nantahala Capital Management LLC (1.05%).
View institutional ownership trends for Celcuity
.

Which major investors are selling Celcuity stock?

CELC stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp.
View insider buying and selling activity for Celcuity
or view top insider-selling stocks.

Which major investors are buying Celcuity stock?

CELC stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Granite Point Capital Management L.P., Nantahala Capital Management LLC, G2 Investment Partners Management LLC, Gagnon Advisors LLC, Manatuck Hill Partners LLC, Gagnon Securities LLC, and Bleichroeder LP.
View insider buying and selling activity for Celcuity
or or view top insider-buying stocks.

How do I buy shares of Celcuity?

Shares of CELC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celcuity's stock price today?

One share of CELC stock can currently be purchased for approximately $26.90.

How much money does Celcuity make?

Celcuity has a market capitalization of $340.29 million. The company earns $-9,470,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does Celcuity have?

Celcuity employs 30 workers across the globe.

What is Celcuity's official website?

The official website for Celcuity is www.celcuity.com.

Where are Celcuity's headquarters?

Celcuity is headquartered at 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446.

How can I contact Celcuity?

Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The company can be reached via phone at (763) 392-0767.


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.